Tranexamic acid for traumatic brain injury? Old drug raises new debate

Damian Palus, Aleksandra Cegła, Alan Majeranowski, Andrzej Mital, Michał Krakowiak, Tomasz Szmuda, Paweł Słoniewski

Review paper

PDF

Effectiveness and safety of ixazomib–lenalidomide–dexamethasone in high-cytogenetic-risk relapsed/refractory multiple myeloma — results of the Polish Myeloma Group observational study

Marek Hus, Aneta Szudy-Szczyrek, Michał Mielnik, Paweł Leszek Bernatowicz, Jarosław Piszcz, Agnieszka Druzd-Sitek, Maria Czyżewska, Maciej Putowski, Krzysztof Giannopoulos

Case report

PDF

Efficacy of lenalidomide in the treatment of myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U) with the presence of deletion 5q– and trisomy 8+

Oliwia Bachanek-Mitura, Aneta Szudy-Szczyrek, Marek Hus

Case report

PDF

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) — diagnostic and therapeutic challenge

Jarosław Wajs, Małgorzata Lewandowska, Przemysław Kluge, Lucyna Drążek, Dorota Jesionek-Kupnicka

Case report

PDF

Secondary immune thrombocytopenia after Streptococcus infection

Katarzyna Korzeniowska, Artur Cieślewicz, Irmina Wietlicka, Anna Jabłecka

Case report

PDF

Ponatinib in treatment of chronic myeloid leukemia with T315I mutation

Klaudia Cieśluk, Jarosław Piszcz

Case report

PDF